US Drug Recall Register
Class III · Low risk Terminated Initiated Mar 12, 2013 (13 years ago)

Portia

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Tablet/Capsule Specifications: This recall is being carried out due to an out of specification result for appearance.

What was recalled

Portia (levonorgestrel and ethinyl estradiol) Tablets, USP, 0.15 mg/0.03 mg, 28-count tablets (containing 21 pink tablets followed by 7 white tablets) per blister card packaged in 6 blister cards per carton, Rx only, Barr Laboratories, Inc., Pomona, NY 10970, NDC 0555-9020-58.

Recalling firm
Teva Pharmaceuticals USA, Inc.
NDC code
0555-9020-58
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-245-2013

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Estradiol recalls

See all
Class II · Moderate risk Ongoing

Alyacen 7/7/7

Reason Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Glenmark Pharmaceuticals Inc., USA NDC 68462-556-29 D-0588-2026
Class II · Moderate risk Ongoing

Estradiol Gel

Reason Defective Container; packets were found to be either empty or partially full.

ANI Pharmaceuticals, Inc. NDC 70954-531-20 D-0543-2026
Class II · Moderate risk Ongoing

Estradiol

Reason Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0315-2026
Class II · Moderate risk Ongoing

Estradiol

Reason Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0314-2026
Class II · Moderate risk Ongoing

Estradiol

Reason Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0313-2026